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Transcription is regulated by acetylation/deacetylation reactions of histone and nonhistone proteins mediated by enzymes called
KATs and HDACs, respectively. As a major mechanism of transcriptional regulation, protein acetylation is a key controller of
physiological processes such as cell cycle, DNA damage response, metabolism, apoptosis, and autophagy. The deacetylase activity
of class III histone deacetylases or sirtuins depends on the presence of NAD+ (nicotinamide adenine dinucleotide), and therefore,
their function is closely linked to cellular energy consumption. This activity of sirtuins connects the modulation of chromatin
dynamics and transcriptional regulation under oxidative stress to cellular lifespan, glucose homeostasis, inﬂammation, and
multiple aging-related diseases including cancer. Here we provide an overview of the recent developments in relation to the diverse
biological activities associated with sirtuin enzymes and stress responsive transcription factors, DNA damage, and oxidative stress
and relate the involvement of sirtuins in the regulation of these processes to oncogenesis. Since the majority of the molecular
mechanisms implicated in these pathways have been described for Sirt1, this sirtuin family member is more extensively presented
in this paper.
1.Introduction
Acetylation is the addition of an acetyl group at the ε-
amino group of the lysine residues present within histone
and nonhistone proteins and is one of the most extensively
studied posttranslational modiﬁcations [1]. Acetylation is
mediated by enzymes called histone acetyl transferases
(HATs), but since a large number of nonhistone proteins are
targeted by HATs, these enzymes are also called KATs (K-
acetyltransferases) [2]. The removal of the acetyl group is
regulated by the activity of histone deacetylases (HDACs).
Acetylation of histone tails decreases their net positive charge
[3], thereby reducing the chromatin-binding aﬃnity to
DNA, which then becomes more accessible to the tran-
scription initiation complexes and the RNA polymerase [4,
5]. The pattern of the N-terminal histone posttranslational
modiﬁcations mediating transcriptional events is called
“histone code” [6].
Transcriptional regulation of gene expression is a com-
plex process involving several posttranslational modiﬁca-
tions of histone and nonhistone proteins. The balance
between reversible modiﬁcations such as acetylation, phos-
phorylation, methylation, ubiquitination, propionylation,
butyrylation, carbonylation, and ADP ribosylation, occur-
ring within speciﬁc chromatin domains, controls the expres-
sion or silencing of a diverse set of genes [7]. Enzymes reg-
ulating the equilibrium of these modiﬁcations maintain the
chromatin organization and structure, thus ﬁne-tuning the
expression of individual genes. Acetylation of the protruding
histone tails is generally associated with activation of gene
expression whereas deacetylation is linked to inhibition of
gene expression [8]. HDACs exert their repressive function2 Journal of Biomedicine and Biotechnology
on transcription either by condensing the chromatin or as
components of large multiprotein complexes, by recruiting
inhibitory factors to regulatory DNA elements within gene
promoter regions [9]. Transcriptional regulation exerted by
HDACs determines vital cellular processes including cell
cycle progression, apoptosis, autophagy, response to diverse
types of stress, diﬀerentiation, and development [10]. Alter-
ations in HDACs-mediated signaling due to overexpression
or hyperactivity of these enzymes can lead to disturbed
homeostasis and, hence to pathological conditions [11]
including systemic autoimmune [12], Huntington’s [13],
neurodegenerative [14], respiratory [15], and cardiovascular
diseases [16], inﬂammation [17], diabetes [18], cardiac
hypertrophy [19, 20], cancer [21], and conditions such as
ageing [22, 23].
Eighteen eukaryotic HDACs, bearing a common well-
conserved catalytic deacetylase domain, have been identiﬁed
so far and classiﬁed into four classes: I, II, III, and IV
[24]. HDAC1, HDAC2, HDAC3, and HDAC8 are members
of the class I HDACs similar to Saccharomyces cerevisiae
reduced potassium deﬁciency 3 (Rpd3) deacetylase. They
are usually localised in the nucleus and form large mul-
tiprotein complexes which confer to these enzymes strict
speciﬁcityforparticularacetylationsites[25].ClassIHDACs
can be further divided into HDAC1/HDAC2 and HDAC3
subclasses. Class II members (HDAC 4, 5, 6, 7, 9, and
10) are homologous to the yeast Hda1 deacetylase and can
be further subdivided into class IIa (HDAC4, 5, 7 and 9)
and IIb (HDAC6 and 10) [26, 27]. Class II HDACs are
localized in both the nucleus and the cytoplasm to target
histone and nonhistone proteins. HDAC11-related enzymes
are considered to form a separate type of HDACs the class IV
[28].
The class III HDACs or sirtuins consists of seven
members (Sirt1–7) homologous to the yeast HDAC silent
information regulator 2 (Sir2) (Figure 1). The common
characteristic of this class is that they are nicotinamide
adenine dinucleotide (NAD+-) dependent enzymes [29, 30].
The requirement of the NAD+ cofactor and the mitochon-
drial localisation of some sirtuin family members imply a
role of this class of deacetylases in the regulation of the
metabolic homeostasis and suggest that histones are not
their primary targets. Sirtuins show signiﬁcant sequence
and functional diﬀerences from other classes of HDACs in
that they carry out deacetylation via a two-step reaction
that consumes NAD+ and releases nicotinamide (NAM), O-
acetyl-ADP-ribose (AADPR), and the deacetylated substrate
[31]. Sirtuins, although relatively similar to each other
have divergent biological functions due to distinct cell-type-
speciﬁc subcellular localisation of each member of the family
[31]. In particular, Sirt1 is located in both the nucleus
and the cytoplasm, Sirt2 in the cytoplasm, Sirt3, 4, and 5
are mitochondrial, and Sirt6 and 7 are exclusively nuclear
[32, 33]. Apart from intracellular localization, Sirt1, 3, and 5
diﬀerfromSirt2,4,and6inthetypeofreactiontheycatalyse.
Sirt1, 3, and 5 are NAD+-dependent deacetylases catalyzing
the deacetylation of histones and nonhistone proteins,
whereas Sirt6 is a NAD+-dependent ADP ribosyltransferase
(ART) mediating mitochondrial protein ribosylation; Sirt2
and4ex ertbothN AD +-dependentHDACandARTactivities
[34]. Although the enzymatic activity of Sirt7 as well as its
speciﬁc substrates have not yet been determined, it has been
shown that it resides in the nucleoli and regulates the RNA
polymerase I (Pol I) transcriptional machinery [35].
The uniqueness of sirtuins is that their function as
transcriptional regulators is directly linked to intracellular
energetics. Accumulating evidence indicates that sirtuins
participate in the coordination of several apparently dis-
p a r a t ec e l l u l a rf u n c t i o n ss u c ha sc e l lc y c l e ,r e s p o n s et o
DNA damage, metabolism, apoptosis, and autophagy [29].
These observations suggest that detailed characterization of
the function of these enzymes under diverse cellular stress
conditions will oﬀer useful information towards designing
novel compounds for therapeutic intervention in a wide
range of apparently unrelated diseases including diabetes,
neurodegenerative disorders, respiratory and cardiovascular
diseases, and cancer. This paper will focus on Sirt1 since its
physiological role has been more extensively studied, and
the evidence regarding the activity of other sirtuins family
members is still scarce.
2.MolecularMechanismsRegulating
SirtuinsActivity
Several studies have indicated the ability of the histone
deacetylase III family members to deacetylate a wide range
ofsubstrates,thusimplicatingtheseenzymesinabroadspec-
trumofbiologicalfunctions.Hence,consideringthemolecu-
lar circuits regulating sirtuins cellular levels (Figure 2)c o u l d
provide the basic knowledge towards developing the means
to control their accumulation for therapeutic beneﬁt.
3.Enzyme Abundance
Sirtuins gene expression has been shown to be under the
controlofnumeroustranscriptionfactorsinvolved inthecell
cycle regulation and apoptosis. Among them the oxidative
stress and DNA damage responsive transcription factor
E2F1, which induces cell cycle progression from G1 to S
phase, directly binds to the Sirt1 promoter upregulating
its gene expression in cells treated with the topoisomerase
II inhibitor etoposide [36]. E2F1 phosphorylation by the
stress-responsive kinase ataxia telangiectasia mutated (ATM)
appears to be a prerequisite for E2F1-mediated regulation
of Sirt1 gene expression [36]. In turn, the deacetylation
function of Sirt1 inhibits E2F1’s transcriptional activity [36].
The tumor suppressor p53, which is one of the most
extensively mutatedproteins in cancers,is a stress-responsive
transcription factor that has also been shown to aﬀect Sirt1
gene expression. Two functional p53-binding sites have been
identiﬁed in the regulatory region of the Sirt1 promoter,
and a complex regulatory network has been described
to elucidate the modulation of Sirt1 gene expression in
mammalian starved cells [37]. In particular, the activated
in nutrient-deprived mammalian cells, forkhead box O
transcription factor FOXO3a forms a complex with p53,
whichisrecruitedtothetwop53-bindingsitespresentwithinJournal of Biomedicine and Biotechnology 3
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Figure 1: Schematic representation of human sirtuins family members 1–7, NAD-dependent catalytic domain (gold) (NAD-binding
pocket), zinc-binding domain (black), and their intracellular localization.
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Figure 2: Factors involved in the regulation of Sirt1 gene expression and enzymatic activity.
the Sirt1 promoter, thus stimulating Sirt1 gene expression
[37]. On the contrary, in normal nutrient conditions, p53
mediates repression of Sirt1 gene expression [37], which
is a result of functional cooperation between p53 and the
epigenetically regulated repressor hypermethylated in cancer
1( H I C 1 )[ 38]. Thus, transcriptional activity and tumor
suppressor functions exerted by p53 are indirectly regulated
by HIC1 mediated repression of Sirt1 gene expression [39].
Furthermore, c-Myc upregulates Sirt1 gene expression, and
in turn Sirt1-mediated c-Myc deacetylation leads to c-Myc
protein degradation [40–42].
Another recently reported pathway regulating Sirt1 gene
expression in response to acute metabolic changes involves
the ﬁne tuning of the association between the redox sensor
carboxy terminal of E1A-binding protein (CtBP) and HIC1
[43].ThetranscriptionalrepressionactivityofCtBPdepends4 Journal of Biomedicine and Biotechnology
on NADH levels, and in particular high NADH levels
promote CtBP dimerization as well as its interaction with
other transcriptional repressors such as HIC1 [44–47].
CellularredoxchangessensedbyCtBPaltertheaﬃnityofthe
CtBP forHIC1 leading toa reductionof CtBP recruitment to
Sirt1 promoter and hence derepression of its gene expression
[43].
Sirt1 cellular levels are regulated by both p53 and E2F1
not only at the transcriptional but at the translational level
as well. MicroRNA 34a (miR-34a) and miR449a, which are
the p53 and E2F1 transcriptional targets, respectively, have
been shown to inhibit Sirt1 expression [48, 49] resulting
in p53 acetylation and induction of p53-dependent apop-
tosis. In addition miR199a knockdown during normoxia
has been shown to stabilize HIF-1α and Sirt1, whereas
miR199a overexpression downregulates prolyl hydroxylase
2 (PHD2) implying that miR199a regulates HIF-1α levels
by moderating Sirt1 and hence PHD2 activities [50]. Sirt1
cellular levels are also regulated by the RNA-binding protein
HuR, which associates with Sirt1 mRNA leading to increased
Sirt1 mRNA stability and, thus elevated Sirt1 protein levels
[51].
Regarding other members of the sirtuins family,
an estrogen-related receptor (ERRα) responsive element
(ERRE) has been mapped within the mouse Sirt3 pro-
moter region, and colocalization of ERRα and peroxisome
proliferator-activated receptor γ coactivator-1α (PGC-1α)
has been conﬁrmed in the Sirt3 promoter with chromatin
immunoprecipitation assay [52].
4.CatalyticActivity
Sirtuins enzymatic activity is regulated by posttranslational
modiﬁcations. In vitro evidence indicates that dephospho-
rylation at speciﬁc sites targeted by cyclinB/Cdk1 in a cell-
cycle-dependent manner reduces its deacetylase activity [53,
54]. Sirt1 is also phosphorylated by the c-Jun N-terminal
kinase 2 (JNK2) [55] and casein kinase 2 (CK2) [56]. JNK2-
mediated phosphorylation of Sirt1 is associated with the
regulation of its protein stability [55]. Both Sirt1 and CK2
are key regulators of similar biological functions including
chromatin remodeling, cell cycle progression, and survival
or apoptosis [53]. Multiple conserved phosphorylation sites
have been identiﬁed within Sirt1 that are potential targets
for a variety of kinases such as ATM, casein kinase 1 (CK1),
DNA-dependent protein kinase (DNA-PK), extracellular-
signal-regulated kinase (ERK1), glycogen synthase kinase 3
(GSK3), IκB kinase (IKK), and mitogen-activated protein
kinase (MAPK) [54]. Whether these kinases phosphorylate
only Sirt1, other members of the sirtuin class, or Sirt1
phosphorylation by one of these kinases aﬀects other
posttranslational modiﬁcation events, and Sirt1 substrate
selectivity is not known. Recently two members of the
dual-speciﬁcity tyrosine phosphorylation-regulated kinases
(DYRK) DYRK1A and DYRK3, which play important role in
body growth and brain physiology, have been demonstrated
to promote cell survival by phosphorylating Sirt1 and
inducing its deacetylase activity [57].
Like Sirt1, Sirt2 is phosphorylated by Cdk1 indicating
thatthissirtuinfamilymemberisalsoinvolved inthecontrol
of cell cycle. Additional evidence for that is provided by
the fact that cyclinE/Cdk2 complex phosphorylates Sirt2
inhibitingitscatalyticactivity.SincecyclinE/Cdk2isinvolved
in the regulation of the cell cycle progression from G2 to
M phase, inhibition of Sirt2 deacetylase activity mediated
by cyclinE/Cdk2 might be a requirement for the cell cycle
progression from G2 to M phase [58]. On the other side,
overexpression of the CDC14A and CDC14B phosphatases,
which are required for eﬃcient DNA repair, inhibits Sirt2
protein degradation and interferes with adhesion and cell
migration [59].
The active regulator of Sirt1 (AROS) is a 142 amino
acid protein localized in the nucleus that interacts with
Sirt1 and activates its deacetylase function [60]. Although
the molecular mechanism of AROS-mediated activation of
Sirt1 has not been deﬁned, AROS possibly displaces a Sirt1
inhibitor from the deacetylase complex such as the deleted
in breast cancer 1 (DBC1) inhibitor, or it recruits another
cellular factor which induces a conformational change that
activates Sirt1 enzymatic activity [61–63]. It has been shown
that the binding aﬃnity between Sirt1 and DBC1 is critical
for the determination of cancer cell survival or death [64].
As is the case for other classes of deacetylases, acety-
lation is another posttranslational modiﬁcation aﬀecting
the activity of various sirtuin members. For example, p300
acetylates Sirt2 and attenuates its deacetylase activity [65].
The molecular mechanism of p300-mediated inactivation
of Sirt2 is not clear, but acetylated Sirt2 might acquire
diﬀerent conformation that alters its interaction pattern or
aﬃnity with other proteins which facilitate its association
with proteins such as the 14-3-3 β/γ. Interaction of Sirt2
with 14-3-3 β/γ might inﬂuence its subcellular localization,
thereby changing its activity [65].
Sumoylation of Sirt1 has been demonstrated to activate
its deacetylase activity and occurs in the absence of DNA
damage [66]. Exposure of cells to diverse types of stress
conditions such as UV irradiation or hydrogen peroxide
results in Sirt1 desumoylation mediated by the desumoylase
sentrin-speciﬁc protease 1 (SENP1) and inactivation of its
deacetylation function. As a consequence the proapoptotic
Sirt1 substrates such as p53 are acetylated and hence active
and capable to induce cell death [61, 67].
5. Availabilityof Metabolic Cofactors
The availability of NAD+ in cells is a limiting step in the
activation of sirtuins catalytic activity since these enzymes
require NAD+ as a cofactor to exert their function [68].
The basal intracellular NAD levels are maintained relatively
constant [69] by the NAD biosynthetic and salvage path-
ways [70]. The precursor of the biosynthetic pathway of
NAD synthesis is tryptophan and nicotinic acid (NA) or
nicotinamide (NAM) the precursors of the salvage pathway
[71, 72]. Human cells produce NAD+ by converting NAM
in a two-step reaction catalysed by nicotinamide phos-
phoribosyltransferase (Nampt) [73]. The ﬁrst step involvesJournal of Biomedicine and Biotechnology 5
the conversion of NAM to nicotinamide mononucleotide
(NMN) by Nampt. NMN is subsequently utilized by nicoti-
namide/nicotinic acid mononucleotide adenylyltransferase
(Nmnat 1, -2, and -3) to regenerate NAD+ [74]. The
molecular mechanism of nicotinamide-mediated inhibition
of the sirtuins deacetylase activity has been elucidated in
recent reports [75, 76]. Deﬁciency of the NAD+ synthe-
sizing pathways abolishes sirtuins-mediated deacetylation
[74] whereas increased NAD+ levels induce their enzymatic
function [77]; therefore, by consuming NAD+ in order
to exert their eﬀects, sirtuins regulate the ﬂuctuation of
the NAD+/NADH ratio, thereby sensing cellular NAD+
concentration and redox status. For more detailed review
of the relation between sirtuins NAD+/NADH ratio and
oxidative stress see references [77–79].
To summarize, glucose deprivation and metabolic
changes associated with calorie restriction alter the NAD+/
NADHratio[80–83].Sincesirtuinsassociatewithchromatin
and their function is NAD+-dependent, these enzymes
couple changes of the metabolic ﬂux and NAD+ levels with
transcription [81].
6.TranscriptionFactorsAssociated
withSirtuins
Crucial cellular pathways involved in cell growth, diﬀer-
entiation, stress resistance, migration, and metabolism are
modulated by the function of transcription factors whose
activity is regulated by sirtuins including p53 [84–86], FOXO
proteins [87], peroxisome proliferation-activating receptor-
(PPAR-) gamma coactivator-1α (PGC-1α)[ 88], and nuclear
factor-κB( N F - κB) (Figure 3 and Table 1)[ 34, 89, 90].
Several lines of evidence converge to the conclusion
that sirtuins are integrated in the p53 pathway, and their
function depends on the cellular status of p53 [84–86].
Sirtuins and p53 interact at various levels to induce cell
cycle progression, senescence, or apoptosis [85]( Figure 3).
The interplay between HIC1 and p53 regulates Sirt1 gene
expression, and reduction or ablation of HIC1 can lead
to tumorigenesis through Sirt1-mediated deacetylation and
transcriptional inactivation of p53 [84, 85]. Sirt7 has also
been shown to interact with p53 in the mice myocardium
[91]. Apart from the acetylation levels, sirtuins regulate the
subcellular localization of p53, thus determining the cellular
fate under oxidative stress conditions [92].
Acetylation of HIF-1α by arrest-defective protein 1
(ARD1) [93] and p300/CBP-associated factor (PCAF) [94]
plays important role in the regulation of the protein stability
and transcription target selectivity [94] of this transcription
factor. Sirt1 deacetylates and represses HIF-1α transcrip-
tional activity [95] whereas Sirt1-mediated deacetylation of
HIF-2α induces its signaling in hypoxic conditions [96]
suggesting that sirtuins signaling promotes the distinctive
function of HIF-1α and HIF-2α [94, 96, 97]. Given the fact
that HIF-1α and HIF-2α play crucial roles in the cellular
adaptation to metabolic stress by regulating the expression
of several genes involved in glucose metabolism, it is possible
that the extent of their acetylation determines the pathway
of cellular energy production and redox balance depending
on the type of tissue and environmental stress [90, 94–
96, 98]. In accord with this perception, Sirt6 is recruited
by HIF-1α to histone 3 and deacetylates H3 lysine 9 within
the promoter regions of several glycolytic genes repressing
theirgeneexpression,therebyregulatingglucosehomeostasis
[98, 99].
The mammalian redox responsive FOXO transcription
factors provide another example of the role of sirtuins in
the determination of the cellular fate under oxidative stress
conditions [104, 111]. Sirtuins target FOXO transcription
factors under conditions of oxidative stress and determine
their subcellular localisation, protein stability, and transcrip-
tional activity [104, 111]. FOXO are involved in the cell
cycle arrest at the G1-S and G2-M checkpoints [112], in
scavenging reactive oxygen species (ROS) [113], and in the
induction of the expression of genes involved in the DNA
damage response, diﬀerentiation, glucose metabolism, and
apoptosis[112,114].Sirt1-mediateddeacetylationofFOXO3
and FOXO4 under stress induces cell cycle arrest instead of
apoptosis [105]. Sirt2 and Sirt3 have also been shown to
associate with FOXO transcription factors modulating their
transcriptional activity and subcellular localization [107,
115–119]. Therefore, sirtuins by controlling the function of
FOXO transcription factors indirectly exert a pivotal role in
the regulation of multiple cellular processes [104]( Figure 3
and Table 1).
The E2F family of transcription factors is involved in the
control of cell cycle progression, DNA damage response, and
induction of apoptosis [120]. The transition from G1 to S
phase checkpoint involves tight regulation of the E2F tran-
scriptional activity by the pocket proteins retinoblastoma
(pRb)tumorsuppressor,p107 andp130. AcetylationofE2F1
by PCAF facilitates the binding of this transcription factor
to its conserved DNA responsive elements and activation of
gene expression of its targets, including several proapoptotic
factors such as Apaf-1, Bim, caspase 7, and p73 [121].
Sirt1 binds and deacetylates pRb engaging the pRb tumor
suppressor pathway in the oxidative stress-response [122–
124].
Various subunits of the NF-κB family of transcription
factors are acetylated at multiple sites, aﬀecting the DNA-
binding and transcriptional activity of these proteins, thus
modulating the release of proinﬂammatory mediators [125].
Thep65/RelAsubunitphysicallyinteractsandisdeacetylated
by Sirt1 resulting in the inhibition of the NF-κB-mediated
transcription [89, 90, 126, 127]. Deacetylation of NF-κB
and inhibition of its transcriptional activity by Sirt1 and
Sirt6 protects pancreatic β cells from NF-κB inﬂammatory
response and preserves insulin secretion [99, 128].
7. Cellular Response to Stress
Sirtuins substrates are involved in the coordination of
cellular responses to diverse stresses including inﬂammation,
hypoxic stress, and heat shock, thereby regulating cell
survival or death, diﬀerentiation, and endocrine signaling.
In particular, sirtuins regulate the transcriptional activity of6 Journal of Biomedicine and Biotechnology
Table 1: Transcription factors associated with sirtuins.
Sirtuin class Substrate Position Function Reference
K120 Induction of cell cycle arrest [100]
p53 K372 Unknown [86]
K382 Reduction of apoptosis [86, 101]
SIRT1
HIF-1α K674 Negative eﬀect on tumor growth and angiogenesis [95]
FOXO1 K242, K245 and K262
Not known
Transcriptional activation
Inhibition of FOXO1 activity
[102]
[103]
FOXO3a Not known
Induction of cell cycle arrest and resistance to oxidative
stress; inhibition of FOXO-mediated induction of
apoptosis; inhibition of FOXO transcriptional activity
[104, 105]
E2F1 Not known Inhibition of E2F1 transcriptional activity; inhibition
of E2F1-mediated apoptosis [36]
NF-κB K310 of RelA/p65
subunit
Inhibition of NF-κB transcriptional activity and
prevention of the release of proinﬂammatory mediators [89]
Sir2α p53 Not known
Attenuation of p53-mediated transcriptional activity
Inhibition of p53-dependent apoptosis in response to
DNA damage
[106]
SIRT2 FOXO3a Not known DNA binding and activation of target genes [43, 107]
SIRT3 AceCS2 K642 Activation of the acetyl-CoA synthetase activity of
AceCS2 [108, 109]
SIRT5 PGC-1α Not known Unknown [110]
SIRT6 HIF-1α Not known Regulation of glucose homeostasis. Reduction of
glycolysis and increase of mitochondrial respiration [98]
SIRT6 NF-κB Not known Reduction of NF-κB-mediated apoptosis and
senescence [99]
p53
p73
E2F1 PCAF
FoxO3 Cell
survival
UCR
Insulin
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LXR
Cholesterol
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Figure 3: Sirtuins regulate the activity of numerous transcriptional regulators indirectly aﬀecting the outcome of several cellular functions.Journal of Biomedicine and Biotechnology 7
NF-κB, p53, HIF-1α,H I F - 2 α, FOXOs, E2F1, and heat shock
factor protein1 (HSF1), which are involved in the regulation
of aging and aging-related diseases.
8. DNA Damage
In order to protect themselves from the high incidence of
damage that could lead to mutations, genomic instability,
or cell death and the diﬀerent types of DNA damage that
might occur, eukaryotic cells have developed appropriate
mechanisms to detect and repair their damaged DNA.
Eﬃcient repair of the damage requires that the DNA repair
machinery circumvents the barrier formed by the histone
and nonhistone proteins that package DNA into chromatin
and accesses the damaged site in a timely manner. In
this respect, chromatin-remodeling and histone-modifying
enzymesarecrucialfortheabilityofeukaryoticcellstodetect
and repair DNA breaks. Consistent with this notion, several
reports have indicated that acetylases and deacetylases are
recruited in the vicinity of DNA breaks [129].
Direct indication for the involvement of sirtuins in
DNA damage response has been revealed in Sirt1−/− and
Sirt6−/− mice which exhibit increased radiation sensitivity,
chromosomal aberrations, and impaired DNA repair [130,
131]. The involvement of sirtuins in the DNA damage
response was initially suggested by observations demonstrat-
ingincreasedchromatinrecruitmentofSirt1tositesofDNA-
DSB in mammalian cells upon diverse types of DNA damage
including oxidative stress in a manner involving stress-
responsive kinases such as ATM [132–134]. Upon DNA
damage, Sirt1 deacetylates the Nijmegen breakage syndrome
(NBS1) which is a DNA-DSB sensor and repair protein,
thus facilitating the recruitment of other required factors
to the sites of damaged DNA and optimal repair through
homologous recombination (HR) and nonhomologous end
joining (NHEJ) [135]. Sirt1 is also required for the optimal
function of the nucleotide excision repair (NER) pathway.
In particular, it has been shown that Sirt1 impairs NER
by suppressing the xeroderma pigmentosum C (XPC) gene
expression which is essential for the recognition of DNA
lesions and NER initiation [136]. Overexpression of Sirt1
represses proteins with DNA damage repair functions such
as various FOXO family members [105], Ku70 [137], p73
[138],pRb[122],andWernerhelicase(WRN)[139].Further
evidence for the involvement of Sirt1 in the DNA damage
response is provided by the fact that it is transcriptionally
upregulated by breast cancer 1 early onset (BRCA1), which
bindstoDNA-DSBandplaysasigniﬁcantroleinDNArepair
and the maintenance of genomic stability [140]. Overall,
Sirt1 is involved in DNA damage response by modulating the
expression of genes involved in DNA repair and by recruiting
to sites of DSBs factors participating in the processing of
DNA damage.
Sirt6−/− mice display sensitivities associated with deﬁ-
ciencies in base excision repair (BER) such as genomic
instability and enhanced sensitivity to ionizing radiation
and DNA damaging agents [131]. The detailed molecular
mechanisms by which Sirt6 regulates DNA damage repair
has been suggested to involve the function of the DNA-PKcs
which is a kinase that takes part in the NHEJ [141]. Sirt6-
mediated deacetylation of the H3K9 at sites surrounding
DSBs allows DNA-PKcs or other repair factors to access
the DNA lesions [131]. Sirt6-dependent deacetylation of
the C-terminal-binding protein (CtBP) -interacting protein
(CtIP) which promotes DNA end resection and is required
for eﬃcient homologous recombination is another proposed
mechanism for SIRT6-dependent processing of DNA dam-
age repair [134, 142]. Consistently with the role of other
chromatin-modifying enzymes, Sirt6 in response to DNA
damage is recruited to DNA breaks either genome-wide
or locally contributing directly to DNA damage repair or
indirectly by permitting access to the DNA lesions to the
DNA damage repair machinery.
Further researchis required to characterisethe molecular
networks linking transcription and chromatin modiﬁcations
to DNA damage response and repair as well as to elucidate
the role of other sirtuin family members in these processes. It
will also be interesting to determine whether diﬀerent sirtuin
family members are involved in the same or diverse DNA
damage and repair pathways and whether they function in
concert or exert antagonistic eﬀects.
9. The NAD+/NADH Ratio
During glycolysis and citric acid cycle, energy from nutrients
is transferred to NAD+ which is reduced to NADH. NADH
is then oxidized back to NAD+ by transferring its reducing
electrons to electron acceptors and ultimately to oxygen, and
the energy released during this process is coupled to ATP
generation through oxidative phosphorylation (OXPHOS)
[77]. Increasing evidence suggests that marked alterations
in the NAD+/NADH ratio may have detrimental eﬀects on
the cellular fate; therefore, NADH levels are very tightly
regulated in cells [143]. High cytosolic NADH levels result in
reactiveoxygenspecies(ROS)generationandoxidativedam-
age by several mechanisms including providing substrates
for NAD(P)H oxidase and release of iron from ferritin.
Furthermore, high levels of cytosolic NADH can either
promote OXPHOS by increasing the mitochondrial NADH
levels or inhibit OXPHOS by promoting pyruvate to lactate
conversion and reducing the permeability of the voltage-
dependent anion channel (VDAC) in the mitochondrial
outer membrane [143]. Since the eﬀects of altered cytosolic
NADH levels on cell injury are complicated, further studies
are required to resolve this issue.
SirtuinsconsumeNAD+ inordertoexerttheirenzymatic
functions, and by doing so they alter the NAD+/NADH ratio,
therebymodifyingtheredoxstatuswithinthecellsandhence
serving as cellular sensors of reduced glucose and NAD+
availability [23, 67, 74, 75]. Changes in energy or increase
of the NAD+/NADH ratio enhances sirtuins activity and
protein deacetylation implying that there is a close associ-
ation between the cellular redox status and the acetylation
levels within the cells [68]. Indeed, Sirt1 has been shown
to determine survival or apoptosis of renal tubular cells
by ﬁne tuning the ROS scavenger catalase gene expression8 Journal of Biomedicine and Biotechnology
in the presence or absence of intracellular ROS [144]. In
particular, in the presence of high levels of intracellular ROS,
Sirt1 induces FOXO3a-mediated upregulation of catalase
gene expression leading to reduction of oxygen consumption
and ROS levels leading to cell survival [144–146]. Reduction
ofROSlevelsbySirt1isthemechanismunderlyingthedevel-
opment of resistance to oxidative stress which is associated
withaginganddiseasessuchastype2diabetesmellitus[145].
Sirt2-mediated deacetylation of FOXO [107, 116]a n dS i r t 3 -
dependent decrease of ROS production in brown adipocytes
[147] as well as Sirt3 involvement in antioxidants production
and NADPH regeneration [148] suggest that several sirtuin
family members play important role during oxidative stress.
Moreworkisneededtocharacterisethedetailedmechanisms
by which sirtuins contribute to the control of cellular redox
levels,whichpotentiallywillleadtothedevelopmentofnovel
therapeutic approaches for the treatment of diseases typiﬁed
by high-inﬂammatory states.
10. Cell Cycle
The involvement of sirtuins in the sensitisation and repair of
D N Ad a m a g ea sw e l la st h er e g u l a t i o no ft h ec e l l u l a rr e d o x
state implies that these enzymes are involved in the control
of the cell cycle in order to provide the necessary time for
the cells to repair their DNA damage under conditions of
oxidativestress.Multipletranscriptionfactorsplayingcritical
role in the control of cellular proliferation and apoptosis
have been identiﬁed as sirtuin substrates (Table 1); therefore,
changes in sirtuins cellular levels aﬀect the ability of cells to
divide. Sirtuins exert both positive and negative eﬀects on
cell growth promoting and inhibiting cellular proliferation.
Many studies converge to the conclusion that inhibition of
sirtuins is beneﬁcial in cancer treatment, which is consistent
with the negative eﬀects they mediate mainly on the tumor
suppressor p53 preventing senescence and programmed cell
death [149]. Furthermore, increased expression of sirtuins in
cancer cells coincides with pRb hyperphosphorylation and
p16INK4A downregulation [150, 151].
Cell cycle regulation through Sirt1 is carried out by
the deacetylation of three members of the FOXO family of
transcription factors, namely FOXO1, FOXO3a, and FOXO4
[104, 152]. Deacetylation of FOXO alters their interaction
pattern with E2F1 or p53, leading to cell cycle arrest
or apoptosis in a manner dependent on environmental
conditions, tissue characteristics, and cellular metabolic state
[152]. In response to oxidative stress, Sirt1 deacetylates
FOXO3a increasing its ability to cause cell cycle arrest and
preventing it from inducing apoptosis [104]. Cell cycle
arrest is also the result of Sirt1-mediated deacetylation of
FOXO1andFOXO4whichareactivatedbydeacetylationand
induce gene expression of the p27Kip1 cyclin/cdk inhibitor. In
addition, deacetylation of these transcription factors induces
gene expression of the antioxidant manganese superoxide
dismutase (MnSOD) and the DNA repair gene growth arrest
and DNA damage inducible (GADD45), thereby enhancing
the cellular defence to oxidative stress [104, 152]. Taken
together, these observations indicate that in response to
oxidative stress, Sirt1 selectively targets FOXO transcription
factors to their prosurvival subset of transcriptional target
genes, thereby inducing cell cycle arrest and resistance to
oxidative damage. Apart from FOXO, Sirt1 inhibits cellular
proliferation by destabilising c-Myc [40, 153].
The role of Sirt2 in cell cycle regulation has been eluci-
dated in cells overexpressing Sirt2 where it acts as a G2/M
checkpoint regulator preventing chromosomal instability
[53,59,154].Sirt2hasalsobeenshowntodeacetylatetubulin
and cause cell cycle arrest prior to entry into mitosis in
responsetomicrotubuleinhibitorssuchasnocodazole[155].
Studies in Sirt3 null mouse embryonic ﬁbroblasts have
indicated that the main function of this sirtuin family
member is the regulation of the mitochondrial ROS levels
[156]. Sirt3 is normally localised inside the mitochondria
but in response to cellular stress, it can be detected in the
nucleus where it relocates in the presence of overexpressed
Sirt5 [157]. In addition, Sirt3 and Sirt4 have recently been
shown to exert antiapoptotic eﬀects in response to DNA
damage when the levels of NAD+ are extremely low [158].
Sirt6 is a key component of the base excision repair, but
whetheritdelayscellcycleprogressiontoallowtimeforDNA
repairtooccur,itisnotknown[131].Sirt6hasbeenshownto
associatewithtelomeremaintenanceanditsdepletionresults
in abnormal telomere structures, end-to-end chromosomal
fusions, and premature senescence [159].
Sirt7 is localised in the nucleoli and is involved in the
regulation of the RNA polymerase I and the transcription
of the ribosomal gene (rDNA). During mitosis, Sirt7 is
phosphorylated and retains its nucleolar localisation until
telophase when it is dephosphorylated and activated to
resume rDNA transcription [160].
In summary, the detailed role of all sirtuin family
members in the regulation of the cell cycle requires further
investigation in order to understand the link between cell
cycle control and their ability to regulate transcription and
acquire diverse subcellular localisation during diﬀerent cell
cycle phases. Moreover, it is intriguing to investigate whether
each member of the sirtuins family exerts its eﬀect on cell
cycleindividuallyorincombinationwithothersirtuinfamily
members or other cell cycle regulators.
11.Apoptosis
Sirt1 interacts, deacetylates, and thereby negatively regulates
the transactivation function of various key transcription
factors playing central role in the determination of the
cellular fate (apoptosis/survival) such as p53 [85], E2F1
[36], members of the FOXO family of transcription factors
[111], NF-κB[ 89], HIF-1α [95] and the DNA-PKcs subunit,
and DNA damage end-joining protein Ku70 [161]( Table 1).
Sirt1 deacetylates several sites of the tumor suppressor
p53 including K320, K372, and K382, which are selectively
acetylatedbyPCAFandp300underdiversestressconditions,
thus antagonising senescence or inducing either cell cycle
arrest or apoptosis [94]. Hyperacetylation of p53 enhances
its transactivation function consequently leading to the
increase of the gene expression of its proapoptotic targets.Journal of Biomedicine and Biotechnology 9
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Figure 4: Role of sirtuins in the celluar response to stress.
Sirt1-dependent deacetylation of p53 reduces the ability of
p53 to induce gene expression of its proapoptotic targets,
thereby suppressing apoptosis in response to oxidative stress
and DNA damage ([85]a n dFigure 4). Besides the control of
p53 activity, Sirt1 regulates the proapoptotic function of the
proapoptotic p53 target Bax by retaining it in the cytoplasm
in complex with the hypoacetylated form of Ku70 and
preventing it from translocating to the outer mitochondrial
membrane to induce apoptosis [162, 163]. Upon cellular
stress conditions such as UV irradiation, Ku70 is acetylated
by PCAF and dissociates from Bax which is now able to
i n d u c ec e l ld e a t h[ 163].
Similarly to p53, the activity of FOXO transcription
factors is regulated by acetylation and deacetylation mod-
iﬁcations. Sirt1 inhibits the ability of FOXO3a to promote
apoptosis by blocking gene expression of the proapoptotic
Bim, Puma, and TRAIL which are FOXO3a transcription
targets in a cellular context manner [161, 164]. Furthermore,
Sirt1 regulates cellular apoptotic responses through the
E2F1/p73 pathway [121], and it is important in controlling
cell death in hypoxic and heat shock conditions by increasing
the activity of HIF-2α [96] and heat shock factor 1 (HSF1)
[165]. Cleavage of Sirt1 by caspase is another possible
pathway through which this deacetylase induces apoptosis,
but the necessity of this cleavage for the initiation of
apoptosis has not been conﬁrmed [166, 167].
It appears that Sirt1 has both negative and positive
eﬀects on apoptosis since by deacetylating p53 and FOXO
transcription factors, it suppresses apoptosis [168]w h e r e a s
in response to TNFα signaling by deacetylating RelA/p65,
it inhibits the transcriptional activity of the antiapoptotic
transcription factor NF-κB[ 61, 89].
The role of Sirt3 in apoptosis appears to be more
complicatedsincethissirtuinfamilymemberhasbeenfound
to cause cell death in several nonstressed human cancer
cell lines in which Bcl-2 had been silenced [169]a sw e l l
as in myeloid leukemia cell lines treated with the natural
ﬂavonoid kaempferol [170], whereas both Sirt3 and Sirt4
have been shown to be required for the maintenance of
the mitochondrial NAD+ in genotoxic stress conditions and
h e n c ec e l ls u r v i v a l[ 109, 158].
It has recently been demonstrated that Sirt5 interacts
with cytochrome c in the mitochondrial membrane [148,
171] but the functional consequences of the Sirt5-dependent
deacetylation of cytochrome c and in particular whether this
modiﬁcation has any impact on apoptosis have not yet been
elucidated.
Sirt7 depletion by RNAi led to inhibition of cell growth
and induction of apoptosis in U2OS cells [35] and primary
cardiomyocytes [91] postulating that this sirtuin family
member is also essential for cell survival [35, 160] although
its eﬀects are probably tissue-type speciﬁc.
Taken together the aforementioned observations imply
that the design of sirtuin inhibitors to promote apoptosis
should take into consideration whether the targets deacety-
latedbysirtuinsaredeacetylatedbymembersofotherHDAC
families, that sirtuins might have both positive and negative
eﬀects on apoptosis, and that sirtuins do not enhance to
the same extent the transcriptional activity of all the genes
induced by the same transcription factors, and it might
not be suﬃcient to block their catalytic function to achieve
induction of cell death.
12. Autophagy
Autophagy is a cytoprotective process by which eukaryotic
cells degrade damaged or dysfunctional organelles and
proteins with long half-life. The degradation takes place
in the lysosome where the cytoplasmic contents to be
degraded are delivered enclosed in double-walled mem-
brane vesicles called autophagosomes which originate from
the endoplasmic reticulum [172–174]. The fact that the
eﬃciency of the autophagic degradation declines during
aging and the eﬃcient maintenance of autophagy leads to
lifespan extension attracted the interest of several research
laboratories to investigate the signaling pathways regulating
autophagy with the aim to understand the factors involved
in the lifetime determination and the causes of age-related
degenerative diseases. Recent research eﬀorts have shed light
on the biochemical autophagic machinery and the crucial
role of several genes called autophagy-related (Atg) genes in
the execution of this process [175–177].10 Journal of Biomedicine and Biotechnology
Sirtuinsareimportantlongevityfactorsaswell;therefore,
it was hypothesised that lifespan might be determined by
interacting signaling network pathways regulating sirtuins
functions and autophagy. Support to this hypothesis was lent
by the observation that Sirt1−/− and Atg5−/− deﬁcient mice
exhibit partially similar phenotypes as well as that Sirt1−/−
mouse embryonic ﬁbroblasts under starved conditions are
unable to activate autophagy [178]. In addition, transiently
expressed wild type Sirt1 but not its inactive deacetylase
mutant could stimulate basal levels of autophagy [178]. The
molecular mechanisms entailed in Sirt1-mediated regulation
o fa u t o p h a g yh a v en o ty e tb e e ne l u c i d a t e d ,b u ti th a s
been proposed that Sirt1 induces autophagosome formation
by associating and deacetylating the Atg5, Atg7, and Atg8
components of the autophagic machinery in a NAD+-
dependent manner, thus facilitating the assembly of Atg
complexes [172, 178–183].
Apart from its direct eﬀects on the components
of the autophagic apparatus, Sirt1 associates with well-
characterized mediators of autophagy and lifespan such as
mTOR (target of rapamycin) [184] FOXO transcription
factors [111, 183]p 5 3[ 185]a n dE 2 F 1[ 186]. The molecular
mechanisms by which autophagy is negatively regulated by
mTOR are not well established, nevertheless it has been
reported that mTOR inhibition or Sirt1 activation prolong,
lifespan [173, 187]. Sirt1 and FOXO3 interact in response to
oxidative stress, and Sirt1 deacetylates and activates FOXO3
which in turn induces the expression of many autophagy-
related genes stimulating autophagy and cellular stress resis-
tance [111]. Several signaling pathways link autophagy and
the tumor suppressor p53, which has been shown to exert
both negative and positive eﬀects on this process [188, 189].
It appears that only cytoplasmic p53 can induce autophagy
in a manner involving the E3 ligase activity of HDM2
[189]. It is not known whether Sirt1 exerts its eﬀects on
autophagy through p53 by aﬀecting the tumor suppressor’s
subcellular localisation or protein stability [190]. E2F1 is a
transcriptional regulator of autophagy as it upregulates the
expression of several ATGs as well as the damage-regulated
autophagy modulator (DRAM) [186]. Since Sirt1 modulates
E2F1’s transcriptional activity [36, 121], it is possible that
Sirt1-determined acetylation status of E2F1 mediates its
eﬀects on autophagy.
There are not many reports in the literature that address
the role of the other sirtuin family members in autophagy
apart from Sirt2 that has been shown to deacetylate FOXO1
and dissociate its complex with Atg7 leading to apoptosis
[191]. Other open questions in relation to the regulation
of autophagy by sirtuins are whether increasing autophagy
by activating sirtuins would have beneﬁcial eﬀects in terms
of longevity, or it would lead to side eﬀects by aﬀecting
other vital cellular functions in which sirtuins have been
implicated.
13.SirtuinsinPathology
Sirtuins are key components of a broad range of biological
processes, which are directly or indirectly linked to aging.
Sirtuins can regulate the aging process partly through their
ability to connect the nutritional status of the cell to
chromatin modiﬁcations and regulation of gene expression
[192, 193]. Their role as longevity mediators is due to their
activity as modulators of several calorie restriction (CR)
pathways [192]. CR extends life span by shifting the glucose
metabolism toward respiration [68] followed by possible
alterations of the NAD+/NADH ratio, modulation of the
sirtuins deacetylase or ADP ribosyl-transferase activity [81],
and slow rate of ROS generation which correlates with
increased longevity [194]. Aging process and several age-
related diseases such as diabetes [128, 195], cardiovascu-
lar [196], neurodegenerative [197], respiratory [198], and
autoimmune diseases [12], and cancer [22, 29, 34, 69, 199]
on the other side are accompanied by elevated redox cellular
content or low-grade chronic, proinﬂammatory stress [32].
In view of the fact that sirtuins are involved in the regulation
of the aging process and in sensing oxidative stress, it has
been suggested that sirtuins could play a vital role in the
development of a variety of aging diseases and their function
could be targeted for therapeutic beneﬁt in these diseases.
Here the role of the most extensively studied member of the
sirtuin family, Sirt1, in tumorigenesis and as a target for the
development of anticancer therapeutics will be discussed.
14. Sirt1inOncogenesis
The role of Sirt1 in tumorigenesis appears to be complex as
this protein has been associated with oncogenic and tumor
suppressor function, and both elevated and decreased levels
have been detected in diﬀerent types of cancer suggesting
that Sirt1 functions in tumorigenesis are tissue-type and
context speciﬁc [149, 200, 201]. For example, increased
Sirt1 levels have been identiﬁed in acute myeloid leukaemia
(AML) [202] and colon cancer where Sirt1 might promote
proliferation and survival [203] or cell growth inhibition
[204]. Both increased and reduced levels of Sirt1 have been
detected in prostate cancer [130, 205] and decreased levels in
ovarianandgliomacancers[37,130]whichispossiblydueto
defectsintheactivityoftumorsuppressorgenesthatregulate
its gene expression [38].
Sirt1 determines changes in gene transcription and
most of its eﬀects in oncogenesis by deacetylating and
thus regulating the function of a large number of tumor
suppressors or oncogenes (Table 1)s u c ha sp 5 3[ 86, 106],
FOXOtranscriptionfactors[104,105],p73[206],pRb[122],
PML [101], Ku70 [163], hTERT [207]M y o D[ 208], NF-κB
[209], and BCL6 [210].
Sirt1 is a direct eﬀector of p53 transcriptional activity
regulating the gene expression of p53 targets involved in
cell cycle arrest (CDKN1A encoding p21WAF-1/CIP-1)a n d
apoptosis (Bax) under DNA damage conditions as well as
p53 protein stability [84, 94]. In turn Sirt1 gene expression
is under the control of the p53-HIC1 loop [85, 211].
The precise role of Sirt1 in tumorigenesis is, therefore,
dependent on the presence and activity of p53 [149]. Sirt1-
mediateddeacetylationofFOXOhasbeenshowntopromote
ubiquitinationanddegradationofthesetranscriptionfactorsJournal of Biomedicine and Biotechnology 11
[212]a sw e l la st oi n d u c eF O X O - d e p e n d e n tc e l lc y c l ea r r e s t
and evasion of apoptosis in response to DNA damage [104,
105]. Deacetylation of pRb in a Sirt1-dependent manner
has been suggested to reverse cell cycle arrest after DNA
damage repair has taken place [122]. Another mechanism
by which Sirt1 promotes cell survival is by deacetylating
E2F1, thereby repressing its transcriptional activity and
preventing the induction of the E2F1/p73 apoptotic pathway
in response to DNA damage [121]. One of the major
functions of Sirt1 is the regulation of inﬂammation through
deacetylation of the proinﬂammatory transcription factor
NF-κB[ 209] and consequent modulation of gene expression
of various cytokines (TNFα, ICAM-1 (intercellular adhesion
molecule-1), IL-6 (interleukin-6), and IL-8) [32, 89, 213]. In
addition, tumorigenesis might be aﬀected by Sirt1 through
itsconsiderableregulatoryeﬀectsonmetabolicprocessesand
the regulation of oxidative stress [214, 215].
Therefore, speciﬁc Sirt1 inhibitors for each type of tissue
needs to be considered in order to increase acetylation in
the case of inactivation of oncogenes or activation of the
expression of proapoptotic genes.
15. Conclusions and Perspectives
Deacetylation reaction catalysed by class III deacetylases
requires the consumption of NAD+ and links chromatin
epigenetic changes and transcriptional regulation with
energy metabolism. Another important diﬀerence between
sirtuins and the other classes of deacetylases is that apart
from deacetylase, some class III family members possess
ADP-ribosyltransferase activity. The mitochondrial locali-
sation of these enzymes and their involvement in acety-
lation/deacetylation processes of mitochondrial proteins is
an additional indication of the coupling between metabolic
networks and acetylation. These characteristics of the sirtuin
family members implicate them in a wide range of diverse
cellular processes ranging from glucose homeostasis, to cel-
lular growth, senescence, stress resistance, and metabolism.
This in combination with the fact that there are seven mem-
bers of the sirtuins family raise the theoretical proposal that
intervention in each one of the diﬀerent cellular processes
modulated by distinct members of the sirtuins family could
increase the speciﬁcity of therapeutics by selectively tar-
geting diﬀerent sirtuins-mediated pathways. Consequently
inhibitors speciﬁc for each member of the sirtuins family
could provide a valuable tool towards understanding the link
of individual sirtuin-member-speciﬁc biological functions to
alternative pathological situations.
Although intensive research in recent years has provided
many answers in relation to the role of sirtuins in human
physiology, there are still many questions and controversies
that require to be addressed. For instance, identiﬁcation
of the factors determining sirtuin members’ tissue as well
as organelle speciﬁc function and whether this is linked
to aging or other physiological or pathological conditions
could facilitate individualisation of treatment with sirtuins
modulators. In addition, it is not known whether speciﬁc
sirtuin family members can only function within particular
pathways, or overlapping synergistic or antagonistic eﬀects
between diﬀerent members of the family could impact on
the same pathways. Moreover, in the case of the sirtuin
members exerting both deacetylase and ADP ribosyl trans-
ferase activity, the conditions determining the one or the
other activity and the relative contribution of each one of
these activities to the development of disease requires further
investigation. Future research will also deﬁne the reason that
Sirt1 overexpression in some cancer tissues has oncogenic
eﬀect and tumor suppressive in others.
Clearly there is a lot of work required to fully understand
the complex role of sirtuins in human physiology and to
hopefully identify new therapeutic uses of sirtuin activators
and inhibitors.
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